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The  Lyt-1,  Lyt-2,  and  Lyt-3 antigens,  as  originally  defined  by alloantisera,  are 
expressed exclusively on T  lymphocytes (1).  Functional  analysis of cells expressing 
these  antigens  has suggested that  Lyt-1  is associated with  helper/amplifier T  cells, 
whereas Lyt-2 and Lyt-3 are markers of cytotoxic and suppressor T  lymphocytes (1). 
Several recent  findings suggest, however, that  the situation  may be more complex. 
Although these subpopulations can often be distinguished by cytotoxic depletion, flow 
cytometry (FCM) analysis has shown that the suppressor/cytotoxic T  cell subset has 
Lyt-1, although in clearly lower amounts per cell than the Lyt-2-, 3- cells (2  4). 
Recently, a  series of monoclonal antibodies  (M.Abs.)  has been  generated against 
murine  cell  surface  antigens  that  react  with  the  Thy-1,  Lyt-1,  Lyt-2,  and  Lyt-3.2 
antigens  (3,  4).  Using  these  M.Abs.,  we  have  examined  normal  mouse  lymphoid 
tissues and reported that a minor subpopulation of lymphocytes exists that is strongly 
Lyt-1  positive,  but  Thy-1  negative.  When  tissue  sections of lymphoid  tissues  were 
examined  by  two-color  immunofluorescence,  cells  expressing  this  phenotype  were 
found in the germinal centers and primary follicles of the lymph nodes and spleen. 
Because  these  areas  are  typically considered  to  be the  sites  of B  lyrnphocytes, this 
finding raised the question of whether a subpopulation of B cells exists that expresses 
Lyt-1 (4). 
In this study, a series of murine B cell lymphomas was screened with various anti- 
T  cell  M.Abs.,  including  anti-Lyt-1,  using  the  fluorescence-activated  cell  sorter 
(FACS).  These  tumors,  in  general,  appear  to  represent  normal  subpopulations  of 
lymphoid cells arrested in discrete stages of differentiation (5). Thus, they provide the 
opportunity  to  examine  the  expression  of antigens  usually  present  on  only  minor 
subpopulations of cells in heterogeneous lymphoid tissues. As a result of these studies, 
we have discovered that otherwise typical B cell lymphomas may express the Lyt-1 
antigen. 
Materials and Methods 
Tumors.  A detailed characterization of the lymphomas used is described  in detail elsewhere 
(6). I 
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Antisera andM.Abs.  Rat anti-mouse M.Abs. directed aganst Thy-l.2 (30-H12 hybridoma), 
Lyt-1 (53-7.3  hybridoma cell line), Lyt-2 (53-6.7  hybridoma), and Lyt-3.2 (53-5.8  hybridoma) 
were described previously (3, 4). Fluorescein isothiocyanate  (FITC) goat anti-mouse p  heavy 
chain serum was obtained from Meloy Laboratories  , Inc., Springfield, Va. FITC mouse (SJL) 
anti-rat Ig serum was prepared as described elsewhere. 1 
Immunofluorescence and FCM.  Immunofluorescence  was  performed  as  described  in  detail 
elsewhere  (7).  Fluorescence  was  measured  by FCM  analysis using  a  FACS  III (B-D FACS 
Systems, Mountain View, Calif.)  (7, 8). 
Toipsin Stripping of Surface Antigens.  10 million cells were suspended  in 30 ml RPMI-1640 
containing  10 mg/ml trypsin (type IX, from porcine pancreas, Sigma Chemical Co., St. Louis, 
Mo.). After incubation for 1 h at 37°C, the digestion was halted by the addition of 3 ml heat- 
inactivated fetal calf serum (HIFCS). The cells were washed twice in medium with 20% HIFCS 
and placed in medium with 20% HIFCS, 10  -4 2-Mercaptoethanol, 2 mM glutamine,  100/x/ml 
penicillin,  and  100  pg/ml  streptomycin.  Cells  were  examined  by  FCM  immediately  after 
enzyme treatment and again after overnight culture. Earlier reports have suggested that Lyt-1 
is trypsin resistant  (3).  However, by using high concentration of enzyme (>5 mg/ml), it was 
possible to remove completely surface Lyt-1 without loss of cell viability. 
Biosynthetic Labeling, Immunoprecipitation, and Gel Electrophoresis.  200 million  WEHI-55 cells 
were labeled with ~S-methionine  for 30 rain in methionine-deficient  RPMI-1640 containing 
I0% dialyzed HIFCS and  1 mCi aSS-methionine  (Amersham Corp., Arlington  Heights, Ill.). 
The cells were chased in 200 ml medium for 5 h, then extracted with 4 ml lysis buffer (0.5% 
Nonidet-P40, Particle Data, Inc., Elmhurst, Ill.; 50 mM Tris;  150 mM NaCI; 0.02% NaNs;  5 
mM  EDTA;  50  mM  phenylmethylsulfonyi  fluoride;  0.2  trypsin  inhibiting  units  per  ml 
Aprotinin  (Sigma  Chemical  Co.),  1  pg/ml  pepstatin  A  (Sigma  Chemical  Co.),  50  mM 
iodoacetamide, pH 8.0) for 30 min at 40C. Nuclei were removed by centrifugation at 5,000 g 
for 20 rain.  Proteins,  immunopreeipitated  with rabbit anti-mouse Ig, anti-Lyt-1  M.Ab.,  and 
fixed Staphylococcus aureus Cowan I strain  (9), were run on  10% sodium dodeeyl sulfate (SDS)- 
polyaerylamide gels as previously described (10). Gels were treated with Enhance (New England 
Nuclear, Boston, Mass.) for fluorography and autoradiographs were made with Kodak X-Omat 
R  film  (Eastman  Kodak  Co.,  Rochester,  N.  Y.)  at  -70°C.  Molecular  weight  standards 
(Pharmacia Fine Chemicals, Div. of Pharmacia, Inc., Piscataway, N. J.) were run in a parallel 
gel lane and were visualized by staining with Coomassie brilliant blue (Bio-Rad Laboratories, 
Richmond, Calif.). 
Results 
Analysis of B  Cell Lymphomas  by FCM.  Recently,  we  examined  a  series  of B  cell 
lymphomas  for  the  presence  of T  cell  differentiation  antigens.  The  most  striking 
finding  was  that  three  surface  Ig  +,  Ia  +  B  lymphomas  unequivocally  expressed  the 
Lyt-1  antigen,  whereas none expressed the Thy-l.2 or Lyt-2 determinants  (Table I). 
The CH5 and WEHI-259 splenic tumors clearly demonstrate  the presence of surface 
IgM  and  Lyt-1,  but  not  the  Thy-l.2,  Lyt-2,  or  Lyt-3.2  antigens.  CH5  was  held  in 
culture  for  5  d,  and  was  still  found  to  express  IgM  and  Lyt-1.  Trace  amounts  of 
Lyt-1 were also detected  on CH4,  CH6,  and  WEHI-5.  The WEHI-55  B  lymphoma, 
which  has  been  maintained  in  continuous  cell  culture  over  the  past  12  too,  also 
expresses  both  surface  IgM/IgD  and  the  Lyt-1  antigen,  but  not  Thy-l.2,  Lyt-2,  or 
Lyt-3.2  (Fig.  1). 
T~ypsin Stripping and Regeneration of Lyt-1 in Culture.  Because  WEHI-259  and  CH5 
have  not  been  established  in  permanent  cell  culture  as  yet,  it  is  possible  that  the 
Lyt-1  antigen  was  passively  acquired  in  vivo.  Hence,  the  splenic  tumor  cells  were 
treated with trypsin, analyzed for removal of Lyt-1, and placed in tissue culture. After 
overnight culture, the trypsin-stripped cells, as well as untreated CH5 and WEHI-259 
cells,  were  again  examined  for  presence  of Lyt-l.  As  shown  in  Fig.  2,  enzymatic 
treatment with trypsin successfully removed the Lyt-1 antigen.  However, within  18 h, 1000  LANIER  ET  AL.  BRIEF  DEFINITIVE  REPORT 
TABLE  I 
Analysis of a Series of Murine B Cell Lymphomas on Expression of T Cell Antigens 
Surface  Anti-Thy-l.2  Anti-Lyt-I  Anti-Lyt-2  Tumor  Strain 
IgM  M.Ab  M.Ab  M.Ab 
CH 1  B 10H2"H4bp/Wts  +  -  -  - 
CH2  B 10H2"H4bp/Wts  +  -  -  - 
CH4  B lOH2"H4bp/Wts  +  -  trace  - 
CH5  B 10H2~H4bp/Wts  +  -  +  - 
CH6  B IOH2mH4bp/Wts  +  -  trace  - 
CH7  Bl0H2~H4bp/Wts  +  -  -  - 
CH8  B 10H2JH4bp/Wts  +  -  -  - 
WEHI-5  (BALB/c ×  NZB)F~  +  -  trace  - 
WEHI-55  (BALB/c ×  NZB)Ft  +  -  +  - 
WEHI-231  (BALB/c ×  NZB)F~  +  -  -  - 
WEHI-259  (BALB/c ×  NZB)F~  +  -  +  - 
Tumor cells were stained for surface IgM with FITC goat anti-mouse #  chain serum. For T  cell 
antigens, cells were treated with M.Ab or medium (control), followed by FITC-SJL anti-rat Ig. 
Analysis was performed using a  B-D FACS Ill system. Analysis of the CH series lymphomas and 
the WEHI-259 B  lymphoma was performed on  in  vivo derived tumor cells. In all cases where 
splenic or ascites tumors were used, >90% of the analyzed cells were of tumor origin, as determined 
by characteristic light scatter profiles and by reaction of>90% of the cells with a monoclonal anti- 
mouse # antibody. 
ANTI-P  ANTI-THY-1.2  ANTI-LYT-1 
M.Ab.  M.Ab. 
ANTI-LYT-2  ANTI-I.YT-3.2 
M.Ab.  M.Ab. 
FIG.  1.  Expression  of  the  Lyt-1  antigen  on  the  WEHI-55  B  cell  lymphoma.  WEHI-55,  an 
established  B  lymphoma  cell  line, was analyzed  by FCM  for the presence of surface Ig and  T  cell 
differentiation  antigens.  Cells  were  incubated  with  FITC  goat  anti-mouse  ~  chain  serum  (A),  rat 
anti-Thy-l.2  M.Ab.  (B),  rat  anti-Lyt-1  M.Ab.  (C),  rat  anti-Lyt-2  M.Ab.  (D), and  rat  anti-Lyt-3.2 
M.Ab.  (E).  15,000  cells  were  analyzed  using  a  B-D  FACS  III system.  In  the  above  figures,  the 
fluorescence  histogram  of the  stained  populations  was  superimposed  over  the  histogram  of the 
autofluorescence  control  (X  axis  ~  fluorescence  intensity  increasing  left  to  right,  linear  scale,  128 
channels;  Y  axis -  number  of cells). 
>90% of the trypsin-stripped cells again expressed Lyt- 1 in the same quantity as the 
untreated control cells. 
Immunoprecipitation of Immunoglobulin and Lyt-1 from  WEHI-55.  Lyt-1  has been im- 
munoprecipitated from normal thymocytes after surface-labeling with 12sI and lacto- 
peroxidase, and has been shown to be a  glycoprotein of ~67,000-70,000  mot wt  (3, 
11). In addition,  a  higher molecular weight  form of Lyt-1 was identified  by immu- LANIER ET AL.  BRIEF DEFINITIVE REPORT 
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FXG. 2.  Trypsin stripping and regeneration of Lyt-I on the WEHI-259 B cell lymphoma. WEHI- 
259 splenic tumor cells were incubated with 10 mg/ml trypsin for 1 h at 37°fi1, analyzed by FCM 
for removal of Lyt-1, and placed in culture overnight. (A) Untreated WEHI-259 cells stained with 
rat anti-Lyt-1 M.Ab., followed by FITC SJL anti-rat Ig serum. (B) Trypsin-treated WEHI-259 cells 
stained  for Lyt-1 immediately after enzyme treatment.  (C)  Untreated  cells analyzed  for Lyt-1 
expression after overnight  culture.  (D)  Trypsin-treated  WEHI-259 cells stained  for Lyt-1 after 
overnight culture. The data are presented as described in the legend to Fig. 1. Note the considerable 
reduction in Lyt-1 antigen expression immediately after trypsin treatment (B vs. A). After overnight 
culture, Lyt-I is again expressed (D vs. B). Similar results were found with the CH5 tumor (not 
shown). 
noprecipitation after surface-labeling of carbohydrates with [3H]borohydride (11). We 
used  biosynthetic  labeling  of WEHI-55  cells  with  aSS-methionine,  followed  by im- 
munoprecipitation  with  anti-Lyt-1,  to see if the  molecular  form of Lyt-1  on this  B 
lymphoma is similar to Lyt-1  from T  cells.  Fig.  3 shows the anti-Ig, anti-Lyt-1, and 
control immunoprecipitations  from WEHI-55. The anti-Ig serum specifically immu- 
noprecipitated  a single light chain and two heavy chains that correspond in size to 8 
chain  and ~  chain  (75,000 and 85,000 mol wt,  respectively). Thus, the Lyt-1  glyeo- 
protein expressed on WEHI-55 shows a similar structure to the Lyt-1 glycoprotein on 
thymocytes. 
Discussion 
Previous studies  have implied  that  Lyt-I is only present  on thymus-derived  lym- 
phocytes and that this molecule is associated with certain specific functional subsets 
of T  cells  (1,  2).  However,  using  FCM  analysis  and  M.Abs.,  we have  conclusively 
demonstrated  that  certain  B  lymphomas may indeed  express  the Lyt-1  antigen.  Of 
the  11  B  lymphomas  examined,  three  tumors  expressed  high  levels  of the  Lyt-1 
antigen. Furthermore, three other tumors gave weak but detectable reactions with the 
anti-Lyt-1 M.Ab. Although these tumors expressed this presumably "T cell specific" 
antigen,  they  were  otherwise  typical  B  lymphomas.  All  expressed  surface  Ig,  Ia 
antigens, and Fc receptors.  None expressed other T  cell differentiation  antigens such 
as Thy-1, Lyt-2, Lyt-3, or the T30 antigen  (6). 1 
Because such a  large  percentage  of these surface  Ig  + B  lymphomas was found to 
express Lyt-1, it seems that expression of this antigen is probably not due to random 1002  LANIER ET AL.  BRIEF  DEFINITIVE REPORT 
Ftc.  3.  Lyt-I and  immunoglobulin from WEHI-55 cells. WEHI-55 cells were biosynthetically 
labeled with S6S-methionine, extracted with lysis  buffer containing 0.5% NP-40 and immunoprecip- 
itated with (1) rabbit anti-mouse  lg; (2) rat anti-Lyt-I (53-7.3); and (3) staph A alone (background). 
Immunoprecipitates  were electrophoresed on 10% SDS-polyacrylamide  gels under reducing condi- 
tions. 
gene derepression in a transformed cell line. One possibility is that the small subset of 
B lymphocytes, which presumably express Lyt-1, is extremely susceptible to oncogenic 
transformation. At present, there is no evidence to support this hypothesis. It should 
be noted  that  with  respect  to other surface markers,  these  Lyt-1 ÷ tumors are  quite 
heterogeneous (6).1 Moreover, analysis of the expression of differentiation antigens on 
these tumors does not support the idea that  they are from a  homogeneous subpopu- 
lation  of  B  cells.  Another  possibility  is  that  leukemogenesis  selectively  includes 
expression of Lyt- 1 on certain B lymphomas. Along these lines, it also is conceivable 
that  normal  B  cells  express  Lyt-1  in  undetectable  amounts.  However,  the  rapid 
proliferation  and  increase  in  cell  size  associated  with  transformation  may  increase 
expression of the existing antigen, therefore allowing detection. 
Of particular  relevance  are  the  recent  reports  that  the  human  Leu-1  antigen  is 
expressed  on  most  human  B  chronic  lymphocytic  leukemias,  but  not  on  normal 
human  B  lymphocytes  (9,  12).  Immunochemical and  functional  studies  have dem- 
onstrated that  human  Leu-1  is probably the homologue of the mouse Lyt-1 antigen 
(9).  Thus, the finding that  murine Lyt-1 and  its putative human counterpart  Leu-1 
are usually expressed on normal T  cells, but are also present on B cell malignancies, 
implies a common mechanism of gene regulation  (9). 
A  final point is that both the Leu-1 and Lyt-1 molecules on T  cells have molecular 
weights of ---67,000-70,000 (9,  12). Immunoprecipitation analysis of the Lyt- 1 antigen 
on WEHI-55 has shown a single diffuse band of protein with approximately the same 
average molecular weight. This suggests that the B lymphoma Lyt- 1 protein is similar 
to the T  cell antigen, perhaps with  glycosylation differences.  Bases on  these data,  a 
more extensive examination of normal B lymphocytes is needed to resolve the apparent 
discrepancy of Lyt- 1 expression of B lymphomas vs. normal lymphoid cells. 
Summary 
Although the Lyt-1 antigen has previously been considered a T  cell-specific marker, 
recent  evidence suggests  that  a  population  of Thy-l-,  Lyt-l* cells exists in  normal LANIER ET AL.  BRIEF  DEFINITIVE REPORT  1003 
lymphoid tissues. In this study, we have observed that the WEHI-55, WEHI-259, and 
CH5  B  cell  lymphomas  express  high  levels  of the  Lyt-1  antigen,  as  detected  by 
monoclonal antibodies using the fluorescence-activated cell sorter. Three other B cell 
lymphomas of the 11 examined also gave weak but detectable reactions with the anti- 
Lyt-1  monoclonal  antibody.  Except  for  the  expression  of the  Lyt-1  antigen,  these 
lymphomas are typical of cells in the B cell lineage with respect to surface phenotype. 
The  Lyt-1  glycoprotein  immunoprecipitated  from  metabolically  labeled  WEHI-55 
cells  is similar  in structure  to the Lyt-1 glycoprotein on thymocytes. These findings 
are similar  to recent  reports  that  B-type human  lymphocytic leukemia  cells express 
the putative human homologue of Lyt-1, the Leu-1 antigen. 
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